SecBot SecBot
SECBOTREPLAY Home › Report › IDYA

IDYA · IDEAYA Biosciences announced a clinical collaboration with AstraZeneca…

IDEAYA Biosciences, Inc. · 8-K filed Apr 9, 2026 at 06:01 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Apr 9, 2026 at 06:01 ET

IDEAYA Biosciences announced a clinical collaboration with AstraZeneca to evaluate its investigational drug IDE849 in combination with AstraZeneca's Imfinzi for treating extensive-stage small cell lung cancer. The study will be globally sponsored by IDEAYA, with AstraZeneca supplying the drug.

  • IDEAYA Biosciences entered into a clinical collaboration agreement with AstraZeneca on April 8, 2026.
  • The collaboration will evaluate IDE849 (a DLL3 TOP1 antibody-drug conjugate) in combination with Imfinzi (durvalumab) in extensive-stage small cell lung cancer (SCLC).
  • IDEAYA will sponsor the global Phase 1 clinical trial, while AstraZeneca will supply Imfinzi.
  • The trial is part of a broader multi-site global Phase 1 study in DLL3 upregulated solid tumors, including SCLC, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access